SIOUX FALLS, South Dakota, April 27, 2017
Kasten, Inc. (OTC Pink: KAST) has completed its acquisition through the merger of DAKOTA Life Sciences, now a wholly owned subsidiary of Kasten, Inc. The cashless transaction was accomplished by a 42 million share block issuance to Thru Pharma, LLC, dba DAKOTA Life Sciences.
Concurrent with this merger, Kasten, Inc. also reduced the number of shares outstanding from 127.5 million shares to 62.5 million shares. “We are glad to be part of the Kasten family,” said Steven Keough, President and COO of Kasten/DAKOTA Life Sciences, and “I am also pleased with the disciplined focus of our new structure and management on achieving long term investor value.”
With a focus on over-the-counter and prescription pharmaceuticals, DAKOTA Life Sciences is well positioned to achieve initial market penetration of products in the antibiotic and antifungal areas.
In addition to proprietary OTC products, the Company is readying high-efficacy prescription pharmaceuticals for accelerated approvals from the U.S. Food and Drug Administration.
About Us: Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals designed to prevent and treat serious conditions arising both in hospital and community settings. We are principally focused on delivering solutions to those people who cannot afford to miss a day of work, but whom are burdened by high risk of morbidity and healthcare costs.
Steven J. Keough
President, Kasten/DAKOTA Life Sciences
522 N. Main Avenue #202
Sioux Falls, SD 57104